Endocrine

, Volume 60, Issue 2, pp 355–361 | Cite as

Longitudinal AddiQoL scores may identify higher risk for adrenal crises in Addison’s disease

  • Gesine Meyer
  • Maike Koch
  • Eva Herrmann
  • Jörg Bojunga
  • Klaus Badenhoop
Original Article

Abstract

Purpose

Several studies have shown a reduced quality of life (QoL) in patients with Addison’s disease (AD), but investigations of QoL over a long-term course are lacking. Adrenal crises (AC) are life-threatening complications in AD. The purpose of this prospective study was to test whether the repeated use of QoL-questionnaires can detect prodromal periods of an AC.

Methods

110 patients with AD were asked to complete the disease specific-QoL questionnaire AddiQoL and a short questionnaire about adverse events once monthly over a period of ten months. AC was defined if at least two of the following symptoms were reported: (a) hypotension, (b) nausea or vomiting, (c) severe fatigue, (d) documented hyponatremia, hyperkalemia, or hypoglycemia, and subsequent parenteral glucocorticoid administration was carried out.

Results

Prevalence of AC was 10.9/100 patient years. AddiQoL scores in patients with AC showed a trend (p = 0,08) to a wider fluctuation over time. Subjective precrises not meeting the criteria for AC were reported by 31 patients who had significantly lower AddiQoL scores (p = 0,018).

Conclusions

These are the first data showing the course of QoL during a period of ten months in patients with AD. Incidence of AC exceeds previous data. Our data show, that subjective precrises in AD associate with lower QoL. AC, as well as precrises affect intraindividual AddiQol-scores over time with a trend to a stronger fluctuation. Longitudinal AddiQol scores and self-reporting of precrises via patient diaries are additional clinical tools to identify higher risk for critical events.

Keywords

Addison’s disease Adrenal insufficiency Adrenal crises AddiQoL 

Notes

Acknowledgements

We thank Reinhard Santen (Endocrinological Group Practice, Centre for hormonal disorders and metabolic diseases, Frankfurt, Germany), Alexander Mann (Endokrinologikum Frankfurt am Main, Centre for Endocrinology and Metabolism, Rheumatology and Neurology, Germany), Michael Droste (Medicover, ambulatory healthcare centre, Oldenburg, Germany), Antje Spens (Ambulatory healthcare centre for metabolic diseases, Leipzig, Germany), Nina Krause and Martin Merkel (Endokrinologikum, ambulatory healthcare centre, Hannover, Germany) and the patient support group “Netzwerk“ for their support in recruitment of patients and acquisition of data. Special thanks to our study coordinator Maria Sandler. This study was supported by the European Union 7th framework Health programme FP7 with the acronym EURADRENAL under the grant agreement 2008-201167.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    S. Hahner, M. Loeffler, B. Bleicken et al., Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. Eur. J. Endocrinol. 162, 597–602 (2010)CrossRefPubMedGoogle Scholar
  2. 2.
    L.C. Smans, E.S. Van der Valk, A.R. Hermus, P.M. Zelissen, Incidence of adrenal crisis in patients with adrenal insufficiency. Clin. Endocrinol. 84, 17–22 (2016)CrossRefGoogle Scholar
  3. 3.
    S. Hahner, C. Spinnler, M. Fassnacht, et al., High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. J. Clin. Endocrinol. Metab. 100, 407–416 (2015)CrossRefPubMedGoogle Scholar
  4. 4.
    G. Meyer, K. Badenhoop, R. Linder, Addison’s disease with polyglandular autoimmunity carries a more than 2.5-fold risk for adrenal crises: German Health insurance data 2010-2013. Clin. Endocrinol. 85, 347–353 (2016)CrossRefGoogle Scholar
  5. 5.
    K. White, W. Arlt, Adrenal crisis in treated Addison’s disease: a predictable but under-managed event. Eur. J. Endocrinol. 162, 115–120 (2010)CrossRefPubMedGoogle Scholar
  6. 6.
    T.H. Puar, N.M. Stikkelbroeck, L.C. Smans et al., Adrenal crisis: still a deadly event in the 21st century. Am. J. Med. 129(339), e1–e9 (2016)Google Scholar
  7. 7.
    B. Bleicken, S. Hahner, M. Loeffler et al., Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. Eur. J. Endocrinol. 159, 811–817 (2008)CrossRefPubMedGoogle Scholar
  8. 8.
    S. Hahner, M. Loeffler, M. Fassnacht et al., Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J. Clin. Endocrinol. Metab. 92, 3912–3922 (2007)CrossRefPubMedGoogle Scholar
  9. 9.
    K. Lovas, J.H. Loge, E.S. Husebye, Subjective health status in Norwegian patients with Addison’s disease. Clin. Endocrinol. (Oxf.). 56, 581–588 (2002)CrossRefPubMedGoogle Scholar
  10. 10.
    J. Tiemensma, C.D. Andela, A.A. Kaptein et al., Psychological morbidity and impaired quality of life in patients with stable treatment for primary adrenal insufficiency: cross-sectional study and review of the literature. Eur. J. Endocrinol. 171, 171–182 (2014)CrossRefPubMedGoogle Scholar
  11. 11.
    K. Lovas, S. Curran, M. Oksnes et al., Development of a disease-specific quality of life questionnaire in Addison’s disease. J. Clin. Endocrinol. Metab. 95, 545–551 (2010)CrossRefPubMedGoogle Scholar
  12. 12.
    M. Oksnes, S. Bensing, A.L. Hulting et al., Quality of life in European patients with Addison’s disease: validity of the disease-specific questionnaire AddiQoL. J. Clin. Endocrinol. Metab. 97, 568–576 (2012)CrossRefPubMedGoogle Scholar
  13. 13.
    L. Gagliardi, M.A. Nenke, T.R. Thynne et al., Continuous subcutaneous hydrocortisone infusion therapy in Addison’s disease: a randomized, placebo-controlled clinical trial. J. Clin. Endocrinol. Metab. 99, 4149–4157 (2014)CrossRefPubMedGoogle Scholar
  14. 14.
    J. Langenheim, M. Ventz, A. Hinz, M. Quinkler, Modified-release prednisone decreases complaints and fatigue compared to standard prednisolone in patients with adrenal insufficiency. Horm. Metab. Res. 45, 96–101 (2013)PubMedGoogle Scholar
  15. 15.
    M. Quinkler, R. Miodini Nilsen, K. Zopf et al., Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur. J. Endocrinol. 172, 619–626 (2015)CrossRefPubMedGoogle Scholar
  16. 16.
    G. Meyer, A. Hackemann, M. Penna-Martinez, K. Badenhoop, What affects the quality of life in autoimmune Addison’s disease? Horm. Metab. Res. 45, 92–95 (2013)CrossRefPubMedGoogle Scholar
  17. 17.
    A.H. Heald, A. Walther, J.R.E. Davis et al., No difference in mood and quality of life in dhea-s deficient adults with addison’s disease vs. type 2 diabetes patients with normal DHEA-S levels: implications for management of these conditions. Front Psychol. 8, 764 (2017)CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    M. Henry, P.S. Wolf, I.L. Ross, K.G. Thomas, Poor quality of life, depressed mood, and memory impairment may be mediated by sleep disruption in patients with Addison’s disease. Physiol. Behav. 151, 379–385 (2015)CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    S.R. Bornstein, B. Allolio, W. Arlt et al., Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 364–389 (2016)CrossRefPubMedGoogle Scholar
  20. 20.
    E.S. Husebye, B. Allolio, W. Arlt et al., Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J. Intern. Med. 275, 104–115 (2014)CrossRefPubMedGoogle Scholar
  21. 21.
    H.J. Repping-Wuts, N.M. Stikkelbroeck, A. Noordzij et al., A glucocorticoid education group meeting: an effective strategy for improving self-management to prevent adrenal crisis. Eur. J. Endocrinol. 169, 17–22 (2013)CrossRefPubMedGoogle Scholar
  22. 22.
    P. Tyrer, S. Cooper, M. Crawford et al., Prevalence of health anxiety problems in medical clinics. J. Psychosom. Res. 71, 392–394 (2011)CrossRefPubMedGoogle Scholar
  23. 23.
    P.M. Stewart, B.M. Biller, C. Marelli et al., Exploring inpatient hospitalizations and morbidity in patients with adrenal insufficiency. J. Clin. Endocrinol. Metab. 101, 4843–4850 (2016)CrossRefPubMedGoogle Scholar
  24. 24.
    J. Daniels, E. Sheils, A complex interplay: cognitive behavioural therapy for severe health anxiety in Addison’s disease to reduce emergency department admissions. Behav. Cogn. Psychother. 45, 419–426 (2017)CrossRefPubMedGoogle Scholar
  25. 25.
    J. Daniels, J.M. Turner-Cobb, Adjuvant psychological therapy in long-term endocrine conditions. Clin. Endocrinol. 86, 772–777 (2017)CrossRefGoogle Scholar
  26. 26.
    S. Hahner, N. Hemmelmann, M. Quinkler et al., Timelines in the management of adrenal crisis-targets, limits and reality. Clin. Endocrinol. (Oxf.). 82, 497–502 (2015)CrossRefPubMedGoogle Scholar
  27. 27.
    C. Leblicq, D. Rottembourg, J. Deladoey et al., Are guidelines for glucocorticoid coverage in adrenal insufficiency currently followed? J. Pediatr. 158, 492–498 (2011). e1CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Endocrinology, Department of Internal Medicine 1Goethe-University HospitalFrankfurtGermany
  2. 2.Institut for Biostatistics and Mathematic ModellingGoethe-UniversityFrankfurtGermany

Personalised recommendations